KRYS News and Press, Krystal Biotech Inc. From 05/23/19

The following slide deck was published by Krystal Biotech, Inc. in conjunction with this Read more ...

PITTSBURGH, May 15, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat dermatological diseases, today announced that Krish S. Krishnan, chairman and chief executive officer, will be presenting at ...

Krystal Biotech (NASDAQ: KRYS ): Q1 GAAP EPS of -$0.29  beats by $0.04 . More news on: Krystal Biotech, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

EMA grants PRIME eligibility for KB103 (bercolagene telserpavec)  to treat dystrophic epidermolysis bullosa Krystal Biotech announces five presentations of clinical and preclinical data at the Society for Investigative Dermatology (“SID”) Annual Meeting PITTSBURGH...

Krystal Biotech (KRYS) - The company announced presentations of clinical data for KB103 to treat DEB (dystrophic epidermolysis bullosa) and preclinical data on KB105 for the treatment of autosomal recessive congenital ichthyosis (ARCI) and KB104 for the treatment of Netherton syndrome at t...

PITTSBURGH, April 29, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases announces presentations of clinical data for KB103 to treat dystrophic epidermolysis bullosa, and precli...

The Company Krystal Biotech Inc. ( KRYS ) is a clinical-stage gene therapy company based in Pittsburgh, PA, which is founded in 2015 and has its IPO in September 2017 . It develops novel, "off-the-shelf", topical gene therapies for serious genetic skin diseases. Based on the strength ...

First EMA PRIME eligibility for Krystal Biotech Eligibility based on positive primary analysis of clinical and non clinical data to date PRIME Designation allows for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval PITTSBURGH, Ma...

Krystal Biotech (NASDAQ: KRYS ): FY GAAP EPS of -$0.97. More news on: Krystal Biotech, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Topline-data from Phase 1/2 clinical trial of KB103 (bercolagene telserpavec) for treatment dystrophic epidermolysis bullosa (DEB) to be announced in 1H 2019 Ancoris, a cGMP facility for clinical and commercial production of KB103, is operational following successful completion of...